Valuation: StemCells Inc

Market Cap 49.92M 45.53M 41.91M 38.15M 71.59M 4.63B 75.47M 510M 203M 2.52B 187M 183M 7.91B P/E 2026 *
-2.15x
P/E 2027 * -1.99x
Enterprise Value 49.92M 45.53M 41.91M 38.15M 71.59M 4.63B 75.47M 510M 203M 2.52B 187M 183M 7.91B EV / Sales 2026 *
71.3x
EV / Sales 2027 * 13.1x
Free-Float
100%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 02/08/1988
Director of Finance/CFO 48 01/04/2022
Chief Operating Officer - 21/01/2025
Director TitleAgeSince
Chairman 54 01/01/2013
Director/Board Member 61 28/11/2016
Director/Board Member 66 06/02/2017
Change 5-day change 1-year change 3-year change Capi.($)
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-3.81%+6.95%+88.55% 58.91B
-2.37%-2.22%+22.96%+83.44% 55.24B
-2.19%-6.02%+10.50%+109.19% 45.66B
-1.89%-9.33%+13.03%+20.04% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+1.11%-8.59%+128.56%+655.74% 34.48B
-0.80%-1.73%+75.29%+56.47% 32.5B
-2.17%+19.70%-30.57%+469.42% 31.69B
Average -1.37%-0.66%+33.18%+176.98% 45B
Weighted average by Cap. -1.49%-1.28%+31.63%+151.41%

Financials

2026 *2027 *
Net sales 700K 638K 588K 535K 1M 64.86M 1.06M 7.16M 2.84M 35.36M 2.63M 2.57M 111M 3.81M 3.48M 3.2M 2.91M 5.47M 353M 5.76M 38.98M 15.48M 193M 14.3M 14M 604M
Net income -21.47M -19.58M -18.02M -16.4M -30.78M -1.99B -32.45M -219M -87.17M -1.08B -80.53M -78.84M -3.4B -24.59M -22.43M -20.65M -18.79M -35.26M -2.28B -37.17M -251M -99.85M -1.24B -92.25M -90.31M -3.9B
Net Debt - -
Logo StemCells Inc
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - StemCells Inc